Abstract
Background Immunocompromised patients who do not respond to vaccination are at increased risk of SARS-CoV-2 infections, including hospitalization and death. Tixagevimab/cilgavimab is a monoclonal antibody combination that has been shown to reduce the risk of SARS-CoV-2 infection. We aimed to assess the incidence and outcomes of COVID-19 among severely immunocompromised patients who received tixagevimab/cilgavimab for pre-exposure prophylaxis (PrEP) during the period when the Omicron variant was the dominant circulating variant. Methods We conducted a retrospective cohort study of vaccinated, severely immunocompromised adults who received at least 1 dose of tixagevimab/cilgavimab for SARS-CoV-2 PrEP. The study specifically evaluated those who did not mount an immune response to vaccination, as indicated by a negative anti-spike immunoglobulin G. Results Seventy-one patients (20.3%) developed breakthrough COVID-19 after tixagevimab/cilgavimab administration. Among patients who developed breakthrough infection with COVID-19, 70 (98.6%) had mild disease and were treated as outpatients. Conclusion Our study suggests that tixagevimab/cilgavimab may be efficacious for vaccinated severely immunocompromised patients. Developing a universal vaccine and other long-acting monoclonal antibodies for PrEP in immunocompromised patients against all SARS-CoV-2 variants, as well as potential emerging coronaviruses, holds promise for combating future outbreaks.
| Original language | English |
|---|---|
| Article number | 10.1097/IPC.0000000000001492 |
| Journal | Infectious Diseases in Clinical Practice |
| Volume | 33 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 Sep 2025 |
Keywords
- Food and Drug Administration (FDA)
- electronic medical record
- polymerase chain reaction
- pre-exposure prophylaxis (PrEP)
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- solid organ transplant recipients
Fingerprint
Dive into the research topics of 'COVID-19 Breakthrough Infections in Severely Immunocompromised Patients Who Received Tixagevimab/Cilgavimab for Pre-exposure Prophylaxis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver